Showing Latest Articles
High-density lipoprotein therapeutics and cardiovascular prevention
Journal of Clinical Lipidology, 10/19/2010
Fazio S et al. – Although high–density lipoprotein–cholesterol–increasing lifestyle maneuvers and established high–density lipoprotein drugs such as niacin and fibrates are likely to protect the vasculature, the negative results obtained in trials of a cholesteryl ester transfer protein inhibitor remind us that HDL cholesterol increases are not always beneficial. It is becoming clear that a functional HDL is a more desirable target than simply increasing HDL cholesterol levels. The larger objective of improving high–density lipoprotein functionality (with or without HDL cholesterol level changes) is bound to become the guiding principle for pharmaceutical research in this area. Several new compounds currently being tested bridge the classical aim of increasing HDL cholesterol levels with the novel target of improving high–density lipoprotein function.
